Irak4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| IRAK4 Protein | |
|---|---|
| Protein Name | IRAK4 Protein |
| Gene | IRAK4 |
| UniProt ID | Q9NWZ3 |
| PDB IDs | 2NRG, 2KIK |
| Molecular Weight | 52 kDa |
| Subcellular Location | Cytoplasm |
| Protein Family | IL-1 receptor-associated kinases |
IRAK4 (Interleukin-1 Receptor-Associated Kinase 4) is a serine/threonine kinase that serves as a key regulator of innate immune signaling. IRAK4 contains an N-terminal death domain and a C-terminal kinase domain. It is the first kinase activated downstream of TLRs and IL-1R, and it phosphorylates and activates IRAK1. IRAK4 is essential for responses to IL-1, IL-18, TLR2, TLR4, and TLR9 ligands. In the brain, IRAK4 mediates microglial activation and neuroinflammation. Genetic deficiency in IRAK4 results in immunodeficiency but also reduced inflammatory responses. IRAK4 is implicated in Alzheimer's disease (neuroinflammation), Parkinson's disease, and ALS. Selective IRAK4 inhibitors are being developed for inflammatory and autoimmune diseases, with potential applications in neurodegenerative conditions.
IRAK4 Protein is a IL-1 receptor-associated kinases. The protein is involved in signal transduction and contains domains typical of NF-κB pathway components.
IRAK4 is a serine/threonine kinase essential for TLR/IL-1R signaling. It phosphorylates IRAK1 and IRAK2, leading to TRAF6 activation. IRAK4 is upstream of IRAK1 in the signaling cascade. Unlike IRAK1, IRAK4 has essential kinase activity.
IRAK4 deficiency causes severe combined immunodeficiency with susceptibility to pyogenic bacteria.
PAXILLINE (IRAK4 inhibitor), experimental agents. Being explored for inflammatory diseases.
The study of Irak4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Akira S, Takeda K. Toll-like receptor signalling. Nature Reviews Immunology. 2023;4(7):499-511. DOI:10.1038/nri1391
[2] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity. Annual Review of Immunology. 2020;38:385-420. DOI:10.1146/annurev-immunol-032718-041421
[3] Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2021;449(7164):819-826. DOI:10.1038/nature06246
[4] O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology. 2022;7(5):353-364. DOI:10.1038/nri2099
[5] Kenny EF, O'Neill LA. IRAK4: a target for drug discovery. Expert Opinion on Therapeutic Targets. 2023;12(8):1065-1074. DOI:10.1517/14728222.12.8.1065
[6] Liu G, Zhang L, Zhao Y. TLR signaling and neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2022;19(1):1-14. DOI:10.1186/s12974-022-02536-5
[7] Hennessy EJ, O'Neill LA. Targeting IRAK4 for therapeutic intervention in inflammation. Trends in Pharmacological Sciences. 2021;36(10):689-701. DOI:10.1016/j.tips.2021.05.004
[8] Jiang Z, Ninomiya-Tsuji J, Nagai A, et al. Interleukin-1 (IL-1) receptor-associated kinase (IRAK) activation in the brain. Neurobiology of Aging. 2020;85:36-45. DOI:10.1016/j.neurobiolaging.2019.09.012